These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

677 related articles for article (PubMed ID: 33502455)

  • 1. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
    Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
    JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
    Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
    Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 4. [Efficacy of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei].
    Lei ZY; Ding BH; Wu QY; Luo JL; Li Z; Wang T; Wang YS; Chen YX; Huang LF; He JF; Yang XS; Guan TP; Ruan Q; Wang JH; Tang HS; Wang J; Cui SZ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Dec; 26(12):1179-1186. PubMed ID: 38110280
    [No Abstract]   [Full Text] [Related]  

  • 5. Twenty-years' experience with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP).
    Papantoni E; Ntatsis K; Kyziridis D; Kalakonas A; Hristakis C; Tentes AA
    J BUON; 2021; 26(4):1647-1652. PubMed ID: 34565031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
    Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Validation of Nomograms to Predict Survival in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin.
    Chandrakumaran K; Carr NJ; Mohamed F; Cecil TD; Moran BJ
    JAMA Surg; 2023 May; 158(5):522-530. PubMed ID: 36920381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of causes and prognostic impact of tube occlusion during hyperthermic intraperitoneal chemotherapy for appendiceal pseudomyxoma peritonei.
    Liu Q; Jiao J; Li C; Chen Y; Wang B; Shi J; Yu G
    World J Surg Oncol; 2024 May; 22(1):134. PubMed ID: 38769546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei.
    Beane JD; Wilson GC; Sutton JM; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Holtzman MP; Zureikat AJ; Ahrendt SA; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2019 May; 26(5):1429-1436. PubMed ID: 30623341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peritoneal Spread of Low-grade Appendiceal Tumours - 2 Days of Early Postoperative Intra-peritoneal Chemotherapy Are Enough.
    Rao A; Mui J; Barat S; Matar AA; Alzahrani N; Morris DL
    Anticancer Res; 2021 Nov; 41(11):5569-5575. PubMed ID: 34732427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei.
    Choudry HA; Pai RK; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Ahrendt SS; Holtzman MP; Zureikat AH; Zeh HJ; Bartlett DL
    Ann Surg Oncol; 2018 Jan; 25(1):76-82. PubMed ID: 29110275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of laparoscopic cytoreductive surgery and HIPEC for the curative treatment of low-grade pseudomyxoma peritonei and multicystic mesothelioma.
    Mercier F; Jeremie G; Alyami M; Delphine V; Vahan K; Pascal R; Sylvie I; Guillaume P; Olivier G
    Surg Endosc; 2020 Nov; 34(11):4916-4923. PubMed ID: 31792692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperthermic intraperitoneal chemotherapy in patients with incomplete cytoreduction for appendiceal pseudomyxoma peritonei: a 10-year treatment experience in China.
    Wang B; Ma R; Shi G; Fan X; Rao B; Xu H
    Orphanet J Rare Dis; 2024 Jan; 19(1):8. PubMed ID: 38178189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M
    Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei.
    Sørensen O; Andersen AM; Larsen SG; Giercksky KE; Flatmark K
    Clin Exp Metastasis; 2019 Dec; 36(6):511-518. PubMed ID: 31541325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry.
    Arjona-Sanchez A; Aziz O; Passot G; Salti G; Esquivel J; Van der Speeten K; Piso P; Nedelcut DS; Sommariva A; Yonemura Y; Turaga K; Selvasekar CR; Rodriguez-Ortiz L; Sanchez-Hidalgo JM; Casado-Adam A; Rufian-Peña S; Briceño J; Glehen O
    Eur J Surg Oncol; 2021 Jun; 47(6):1420-1426. PubMed ID: 33298341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis.
    Marcotte E; Dubé P; Drolet P; Mitchell A; Frenette S; Leblanc G; Leclerc YE; Sideris L
    World J Surg Oncol; 2014 Nov; 12():332. PubMed ID: 25380618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
    Lord AC; Shihab O; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2015 Mar; 41(3):396-9. PubMed ID: 25216980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
    Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
    Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
    Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.